Daniel E. Geffken
2021 - Sevion Therapeutics
In 2021, Daniel E. Geffken earned a total compensation of $130.8K as Interim Chief Financial Officer at Sevion Therapeutics.
Compensation breakdown
Other | $130,750 |
---|---|
Total | $130,750 |
Geffken received $130.8K in other compensation, accounting for 100% of the total pay in 2021.
Rankings
In 2021, Daniel E. Geffken's compensation ranked 12,191st out of 12,415 executives tracked by ExecPay. In other words, Geffken earned more than 1.8% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 12,191 | 2nd |
Manufacturing | 5,403 | 2nd |
Chemicals And Allied Products | 2,343 | 1st |
Drugs | 2,068 | 1st |
Biological Products, Except Diagnostic Substances | 443 | 1st |
Geffken's colleagues
We found two more compensation records of executives who worked with Daniel E. Geffken at Sevion Therapeutics in 2021.